Allergan: mixed quarterly report.
(CercleFinance.com) - On Wednesday before Wall Street opened Allergan reported a loss of 12.
05 dollar per share for the third quarter of its fiscal year, against a previous loss of 1.15 dollar.
Excluding extraordinary items, the US pharmaceutical company posted EPS of 4.15 dollars, 11 cents higher than the consensus.
Meanwhile, revenues reached 4.03 billion dollars, up from 3.62 billion dollars in Q3 2016, although the consensus was slightly more optimistic, expecting 4.04 billion dollars.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
05 dollar per share for the third quarter of its fiscal year, against a previous loss of 1.15 dollar.
Excluding extraordinary items, the US pharmaceutical company posted EPS of 4.15 dollars, 11 cents higher than the consensus.
Meanwhile, revenues reached 4.03 billion dollars, up from 3.62 billion dollars in Q3 2016, although the consensus was slightly more optimistic, expecting 4.04 billion dollars.
Copyright (c) 2017 CercleFinance.com. All rights reserved.